1. Home
  2. RIGL vs ASGI Comparison

RIGL vs ASGI Comparison

Compare RIGL & ASGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • ASGI
  • Stock Information
  • Founded
  • RIGL 1996
  • ASGI 2019
  • Country
  • RIGL United States
  • ASGI United States
  • Employees
  • RIGL N/A
  • ASGI N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • ASGI Investment Managers
  • Sector
  • RIGL Health Care
  • ASGI Finance
  • Exchange
  • RIGL Nasdaq
  • ASGI Nasdaq
  • Market Cap
  • RIGL 537.6M
  • ASGI 600.9M
  • IPO Year
  • RIGL 2000
  • ASGI N/A
  • Fundamental
  • Price
  • RIGL $41.64
  • ASGI $20.68
  • Analyst Decision
  • RIGL Buy
  • ASGI
  • Analyst Count
  • RIGL 6
  • ASGI 0
  • Target Price
  • RIGL $39.83
  • ASGI N/A
  • AVG Volume (30 Days)
  • RIGL 652.5K
  • ASGI 83.3K
  • Earning Date
  • RIGL 11-04-2025
  • ASGI 01-01-0001
  • Dividend Yield
  • RIGL N/A
  • ASGI 8.76%
  • EPS Growth
  • RIGL 2698.26
  • ASGI N/A
  • EPS
  • RIGL 6.20
  • ASGI N/A
  • Revenue
  • RIGL $282,076,000.00
  • ASGI N/A
  • Revenue This Year
  • RIGL $59.93
  • ASGI N/A
  • Revenue Next Year
  • RIGL N/A
  • ASGI N/A
  • P/E Ratio
  • RIGL $6.77
  • ASGI N/A
  • Revenue Growth
  • RIGL 79.13
  • ASGI N/A
  • 52 Week Low
  • RIGL $14.63
  • ASGI $14.96
  • 52 Week High
  • RIGL $43.72
  • ASGI $18.55
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 69.25
  • ASGI 47.98
  • Support Level
  • RIGL $34.00
  • ASGI $20.58
  • Resistance Level
  • RIGL $39.56
  • ASGI $20.87
  • Average True Range (ATR)
  • RIGL 2.36
  • ASGI 0.23
  • MACD
  • RIGL 1.09
  • ASGI 0.02
  • Stochastic Oscillator
  • RIGL 91.70
  • ASGI 66.92

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About ASGI abrdn Global Infrastructure Income Fund of Beneficial Interest

abrdn Global Infrastructure Income Fund is a non-diversified, closed-end management investment company. Its objective is to seek to provide a high level of total return with an emphasis on current income by investing in assets that provide necessary services to society.

Share on Social Networks: